TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05670080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Motor imagery is the imagining of action without its physical execution and motor imagery elicits activity in brain regions that are normally activated during actual task performance. The brain perceives real experiences and the visualization process as similar. For this reason, imagery is considered a mental exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Electrotherapy (TENS), cold pack therapy, joint range of motion exercises, and strengthening exercises for the muscles around the shoulder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Electrotherapy (TENS), cold pack therapy, joint range of motion exercises, and strengthening exercises for the muscles around the shoulder.
Study: NCT05302687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: This project aims to evaluate differences in general women's health of women on probiotic and placebo via the use of questionnaire and evaluate differences in immunity of women on probiotic and placebo via blood immunity profiling. To evaluate differences in gut microbiota profiles of women on probiotic and placebo via blood fecal microbiota profiling.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: This project aims to evaluate differences in general women's health of women on probiotic and placebo via the use of questionnaire and evaluate differences in immunity of women on probiotic and placebo via blood immunity profiling. To evaluate differences in gut microbiota profiles of women on probiotic and placebo via blood fecal microbiota profiling.
Study: NCT06182735

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells
Description: Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.
Study: NCT05215366

Intervention type: DIAGNOSTIC_TEST
Intervention: copeptin biomarker in children with febrile seizures
Description: biomarkers increase in children with febrile seizures

Intervention type: DIAGNOSTIC_TEST
Intervention: copeptin biomarker in children with febrile seizures
Description: biomarkers increase in children with febrile seizures

Intervention type: DIAGNOSTIC_TEST
Intervention: copeptin biomarker in children with febrile seizures
Description: biomarkers increase in children with febrile seizures
Study: NCT05275569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: True acupuncture + standard antiemetic treatment
Description: Participants will receive electroacupuncture once daily from day 1 to day 4. The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture + standard antiemetic treatment
Description: The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post-chemotherapy(the antiemetic drugs are the same as the true acupuncture group).
Study: NCT04303000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Overdose Education with Naloxone Distribution
Description: Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with a naloxone kit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Overdose Education
Description: Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with information on where they can obtain a naloxone kit.
Study: NCT04722185

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Veriton SPECT/CT
Description: The Veriton system represents an FDA approved (510k cleared) new generation of SPECT/CT systems. It consists of 12 small gamma cameras arrayed in a circle around the patient, and is coupled to a 64-slice CT system.
Study: NCT05590520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botulinum injection
Description: Botox injection to be injected in internal anal sphincter to see the curative response in comparison to gtn cream application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTN OINTMENT
Description: 0.2%GTN applied on anal canal.
Study: NCT05574179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Inj precedex 200mcg in 1ml given in stat doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Inj.midazolam 5mg/5ml given in stat doses
Study: NCT06312787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-118
Description: Tablets and Suspension for Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-118
Description: Tablets and Suspension for Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-118
Description: Tablets and Suspension for Oral Administration
Study: NCT04909528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level tragus stimulation
Description: Frequency: 20Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulation spot: ear tragus; Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Frequency: 20 Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulate spot: ear lobe. Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)
Study: NCT03543514

Intervention type: OTHER
Intervention: TRIMODAL PREHABILITATION
Description: Trimodal prehabilitation application in the form of:~* Control with the 6-minute walking test and podometer of physical activity~* Dietary advice to be able to perform a hyperproteic diet~* Mindfullnes to improve the emotional level.
Study: NCT06349967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel Combined With Cadonilimab (AK104)
Description: Nab-paclitaxel 100mg/m2 ivgtt d1, d8, d15, q28d; Cadonilimab (AK104) 6mg/kg ivgtt d1, d15, q28d;
Study: NCT06009146

Intervention type: DEVICE
Intervention: Endovascular treatment
Description: Endovascular treatment for infrapopliteal arterial disease.

Intervention type: DEVICE
Intervention: Endovascular treatment
Description: Endovascular treatment for infrapopliteal arterial disease.

Intervention type: DEVICE
Intervention: Endovascular treatment
Description: Endovascular treatment for infrapopliteal arterial disease.
Study: NCT05510960

Intervention type: OTHER
Intervention: Video game & Robotic surgery simulator success
Description: A questionnaire was administered to all participants, asking about their demographic information, surgical experience, hobbies, and previous video game playing experiences.~After the questionnaire, the participants were asked to play the Temple Run (Imangi Studios, NC, USA) and Piano Tiles 2™ mobile games for one month. At the end of the period, with the da Vinci® Skills Simulator™ for one hour, all participants performed four different robotic surgery simulator tasks (Camera Targeting 1, Energy Switching 1, Ring \& Rail 2, Vertical Defect Suturing) that require the ability to apply basic robotic surgery rules and measure surgical skills.

Intervention type: OTHER
Intervention: Video game & Robotic surgery simulator success
Description: A questionnaire was administered to all participants, asking about their demographic information, surgical experience, hobbies, and previous video game playing experiences.~After the questionnaire, the participants were asked to play the Temple Run (Imangi Studios, NC, USA) and Piano Tiles 2™ mobile games for one month. At the end of the period, with the da Vinci® Skills Simulator™ for one hour, all participants performed four different robotic surgery simulator tasks (Camera Targeting 1, Energy Switching 1, Ring \& Rail 2, Vertical Defect Suturing) that require the ability to apply basic robotic surgery rules and measure surgical skills.

Intervention type: OTHER
Intervention: Video game & Robotic surgery simulator success
Description: A questionnaire was administered to all participants, asking about their demographic information, surgical experience, hobbies, and previous video game playing experiences.~After the questionnaire, the participants were asked to play the Temple Run (Imangi Studios, NC, USA) and Piano Tiles 2™ mobile games for one month. At the end of the period, with the da Vinci® Skills Simulator™ for one hour, all participants performed four different robotic surgery simulator tasks (Camera Targeting 1, Energy Switching 1, Ring \& Rail 2, Vertical Defect Suturing) that require the ability to apply basic robotic surgery rules and measure surgical skills.
Study: NCT04873492

Intervention type: OTHER
Group type: OTHER
Intervention: Biological sample collection
Description: Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Biological sample collection
Description: Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.
Study: NCT05333159

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: dapagliflozin 10mg once daily dose canagliflozin100mg once daily dose empagliflozin 0mg once daily dose
Study: NCT05672433

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule without cafestol twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cafestol
Description: Capsule with 6 mg cafestol twice daily
Study: NCT06012097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac gel
Description: using diclofenac as a comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatherapy gel
Description: using Aromatherapy gel as an experimetnal treatment
Study: NCT06491550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144- Part A
Description: Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144- Part A
Description: Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144- Part A
Description: Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144- Part A
Description: Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144- Part A
Description: Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144- Part A
Description: Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.
Study: NCT05050760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCF
Description: DCF:Oxaliplatin (85mg/ m\^2, IV D1,Q3W.Docetaxel: 60 mg/m\^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA\<1.25\^2,40 mg/time,1.25\^2\<BSA\<1.5\^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks
Study: NCT04940234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to a Photo
Description: We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photo of a man. We experimentally vary treatment along two dimensions: whether the man is wearing expert vs. layperson attire and whether the man is white vs. black. We will survey participants' beliefs about the actors' educational attainment and perceived quality as measured by subjects' willingness to accept medical advice for non-urgent health issues or participate in a clinical trial being led by the individual in the photo.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to a Photo
Description: We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photo of a man. We experimentally vary treatment along two dimensions: whether the man is wearing expert vs. layperson attire and whether the man is white vs. black. We will survey participants' beliefs about the actors' educational attainment and perceived quality as measured by subjects' willingness to accept medical advice for non-urgent health issues or participate in a clinical trial being led by the individual in the photo.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to a Photo
Description: We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photo of a man. We experimentally vary treatment along two dimensions: whether the man is wearing expert vs. layperson attire and whether the man is white vs. black. We will survey participants' beliefs about the actors' educational attainment and perceived quality as measured by subjects' willingness to accept medical advice for non-urgent health issues or participate in a clinical trial being led by the individual in the photo.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to a Photo
Description: We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photo of a man. We experimentally vary treatment along two dimensions: whether the man is wearing expert vs. layperson attire and whether the man is white vs. black. We will survey participants' beliefs about the actors' educational attainment and perceived quality as measured by subjects' willingness to accept medical advice for non-urgent health issues or participate in a clinical trial being led by the individual in the photo.
Study: NCT05361837

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single level serratus anterior plane block
Description: Serratus anterior plane block with local anesthetics at the third rib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single level serratus anterior plane block with dexmedetomidine
Description: Serratus anterior plane block with local anesthetics and dexmedetomidine at the third rib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilevel serratus anterior plane block
Description: Serratus anterior plane block with local anesthetics at the third and fifth rib
Study: NCT06491550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Part A
Description: Part A: Participants will be administered a single dose of placebo on Day 1 via IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Part A
Description: Part A: Participants will be administered a single dose of placebo on Day 1 via IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Part A
Description: Part A: Participants will be administered a single dose of placebo on Day 1 via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144- Part B
Description: Part B: Participants will be administered a single dose of AZD4144 on Day 1 and Day 12 via IV infusion.~Participants will be administered multiple doses of AZD4144 from Day 4 to Day 11 via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144- Part B
Description: Part B: Participants will be administered a single dose of AZD4144 on Day 1 and Day 12 via IV infusion.~Participants will be administered multiple doses of AZD4144 from Day 4 to Day 11 via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144- Part B
Description: Part B: Participants will be administered a single dose of AZD4144 on Day 1 and Day 12 via IV infusion.~Participants will be administered multiple doses of AZD4144 from Day 4 to Day 11 via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144- Part B
Description: Part B: Participants will be administered a single dose of AZD4144 on Day 1 and Day 12 via IV infusion.~Participants will be administered multiple doses of AZD4144 from Day 4 to Day 11 via IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Part B
Description: Part B: Participants will be administered a single dose of placebo on Day 1 and Day 12via IV infusion. Participants will be administered multiple doses of placebo from Day 4 to Day 11 via IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Part B
Description: Part B: Participants will be administered a single dose of placebo on Day 1 and Day 12via IV infusion. Participants will be administered multiple doses of placebo from Day 4 to Day 11 via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and Furosemide- Part C
Description: Participants will be administered a single oral dose of 10 mg Rosuvastatin and 1 mg Furosemide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin, Furosemide, and AZD4144 Part C
Description: Participants will be administered a single oral dose of 10 mg Rosuvastatin, 1 mg Furosemide and a single dose of AZD4144 via IV infusion.
Study: NCT04746924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab is a monoclonal antibody formulated for intravenous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab is a monoclonal antibody formulated for intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Ociperlimab is a monoclonal antibody formulated for intravenous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
Study: NCT04711096

Intervention type: PROCEDURE
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.
Description: After preparing the skin with antiseptic solution, a linear high frequency ultrasound probe will be placed abdominal wall between the iliac crest and the costal margin. A Spinal needle 22g attached with flexible tubing to a syringe filled with saline will be used to perform the block then introduced through the skin anteriorly in the plane between the internal oblique and transversus abdominis muscles with its tip lying in the mid axillary line. To assist with identifying these structures, The final position of the probe will to be no further anterior than the anterior axillary line. If satisfactory views are not obtained, the TAP block will not be performed. Hydro dissection with saline (2-5 ml) will be used to separate the fascial layers. After aspiration to exclude inadvertent vascular puncture, 20 ml of the 0.25% bupivacaine will be injected . TAP block will be performed in a similar fashion on the opposite side.

Intervention type: PROCEDURE
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.
Description: After preparing the skin with antiseptic solution, a linear high frequency ultrasound probe will be placed abdominal wall between the iliac crest and the costal margin. A Spinal needle 22g attached with flexible tubing to a syringe filled with saline will be used to perform the block then introduced through the skin anteriorly in the plane between the internal oblique and transversus abdominis muscles with its tip lying in the mid axillary line. To assist with identifying these structures, The final position of the probe will to be no further anterior than the anterior axillary line. If satisfactory views are not obtained, the TAP block will not be performed. Hydro dissection with saline (2-5 ml) will be used to separate the fascial layers. After aspiration to exclude inadvertent vascular puncture, 20 ml of the 0.25% bupivacaine will be injected . TAP block will be performed in a similar fashion on the opposite side.
Study: NCT05361837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilevel serratus anterior plane block with dexmedetomidine
Description: Serratus anterior plane block with local anesthetics and dexmedetomidine at the third and fifth rib
Study: NCT05711368

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Distress tolerance training
Description: It consisted of seven sessions. A 90-minute session will be conducted twice a week for four weeks. The first introductory session will be concerned with helping the student learn how to engage in distress tolerance training and define goals of distress tolerance. At the end of the 1st session, a written plan for every session (time, duration and setting) will be scheduled individually with each student.The next six training sessions will cover three core skills which comprised three sets: Crisis Survival Skills, the skills of Reality Acceptance; and the Skills When the Crisis Is Addiction. The distress tolerance training methods will include individualized interactions, demonstration, and rehearsal, psychoeducation, practice exercises and homework assignments. Follow up between sessions will done using telephone calling and messaging in order to encourage performance homework assignments, and provide help and support when needed particularly at the time of stress. .